Published in Ann Oncol on July 25, 2013
Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) (2015) 0.96
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Jpn J Clin Oncol (2014) 0.96
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? Viruses (2015) 0.92
Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci (2014) 0.89
Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) (2014) 0.85
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. Br J Cancer (2014) 0.82
Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget (2016) 0.81
Targeted Therapies for Brain Metastases from Breast Cancer. Int J Mol Sci (2016) 0.80
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.79
Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol (2014) 0.78
Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA. Breast Care (Basel) (2014) 0.78
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist (2016) 0.77
G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30. Am J Transl Res (2015) 0.76
New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting. Cancer Med (2016) 0.75
Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) (2016) 0.75
Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Viszeralmedizin (2015) 0.75
Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature. Medicine (Baltimore) (2015) 0.75
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study. Oncol Ther (2016) 0.75
Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study. Int J Mol Sci (2017) 0.75
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. Pharmacogenomics J (2016) 0.75
Attitudes and barriers to incident reporting: a collaborative hospital study. Qual Saf Health Care (2006) 3.23
The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc Natl Acad Sci U S A (1995) 2.70
Identification of a putative alternate sigma factor and characterization of a multicomponent regulatory cascade controlling the expression of Pseudomonas syringae pv. syringae Pss61 hrp and hrmA genes. J Bacteriol (1994) 2.45
Antigenic variation of Anaplasma marginale by expression of MSP2 mosaics. Infect Immun (2000) 2.15
[Obstetric anesthesia/analgesia in Spain. Study notes on its historical evolution during the 1st half of this century]. Rev Esp Anestesiol Reanim (1999) 2.01
Expression of multiple outer membrane protein sequence variants from a single genomic locus of Anaplasma phagocytophilum. Infect Immun (2003) 1.70
Ion-dependent inactivation of barium current through L-type calcium channels. J Gen Physiol (1997) 1.67
A chain initiation factor common to both modular and aromatic polyketide synthases. Nature (1999) 1.62
Engineering broader specificity into an antibiotic-producing polyketide synthase. Science (1998) 1.60
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res (1999) 1.54
The annual cycle of primary productivity in a tropical estuary: the inner regions of the Golfo de Nicoya, Costa Rica. Rev Biol Trop (2001) 1.46
Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev (2000) 1.44
A hybrid modular polyketide synthase obtained by domain swapping. Chem Biol (1996) 1.42
[Iatrogenic injury of an aberrant, independent, right hepatic duct (V-VIII segments). Diagnostic and therapeutic difficulties]. Rev Esp Enferm Dig (2008) 1.41
Emerging targeted therapies in triple-negative breast cancer. Ann Oncol (2012) 1.40
Towards a new chronology of ether anesthesia in Europe. Acta Anaesthesiol Belg (1997) 1.39
[Experience with 100 anesthetized patients ventilated with laryngeal mask]. Rev Esp Anestesiol Reanim (1992) 1.39
Fetal cardiotocography and acid-base status during cesarean section. Eur J Obstet Gynecol Reprod Biol (1998) 1.38
[Lung resection surgery in patients with functional limits]. Arch Bronconeumol (1996) 1.38
Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol (2010) 1.35
Antigenic variation of Anaplasma marginale: major surface protein 2 diversity during cyclic transmission between ticks and cattle. Infect Immun (2001) 1.34
Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol (2008) 1.33
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer (2013) 1.31
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol (2008) 1.31
Inactivation of gating currents of L-type calcium channels. Specific role of the alpha 2 delta subunit. J Gen Physiol (1998) 1.27
Activation of protein kinase A modulates trafficking of the human cardiac sodium channel in Xenopus oocytes. Circ Res (2000) 1.22
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol (2012) 1.22
Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. J Biol Chem (2001) 1.20
Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration. J Biol Chem (2000) 1.19
Analysis of seven genes from the eryAI-eryK region of the erythromycin biosynthetic gene cluster in Saccharopolyspora erythraea. Mol Gen Genet (1997) 1.19
Analysis of eryBI, eryBIII and eryBVII from the erythromycin biosynthetic gene cluster in Saccharopolyspora erythraea. Mol Gen Genet (1998) 1.19
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol (1994) 1.18
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer (2001) 1.17
Synthesis and crystal structure of some transition metal complexes with a novel bis-Schiff base ligand and their antitumor activities. Eur J Med Chem (2006) 1.17
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer (2003) 1.14
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol (2010) 1.12
Targeted gene inactivation for the elucidation of deoxysugar biosynthesis in the erythromycin producer Saccharopolyspora erythraea. Mol Gen Genet (1998) 1.12
Elliptic flow of charged particles in Pb-Pb collisions at sqrt[S(NN)] = 2.76 TeV. Phys Rev Lett (2010) 1.12
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer (2000) 1.12
Particle-yield modification in jetlike azimuthal dihadron correlations in Pb-Pb collisions at √s(NN)=2.76 TeV. Phys Rev Lett (2012) 1.11
Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol (2011) 1.10
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol (2011) 1.09
Transverse momentum distribution and nuclear modification factor of charged particles in p+Pb collisions at sqrt[s(NN)] = 5.02 TeV. Phys Rev Lett (2013) 1.08
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology (2001) 1.07
Early textbooks on anaesthesia. Anaesthesia (1992) 1.06
Higher harmonic anisotropic flow measurements of charged particles in Pb-Pb collisions at sqrt(s(NN)) = 2.76 TeV. Phys Rev Lett (2011) 1.05
Knowledge-based design of bimodular and trimodular polyketide synthases based on domain and module swaps: a route to simple statin analogues. Chem Biol (1999) 1.05
Glucose regulation of cephamycin biosynthesis in Streptomyces lactamdurans is exerted on the formation of alpha-aminoadipyl-cysteinyl-valine and deacetoxycephalosporin C synthase. J Gen Microbiol (1986) 1.05
Systematic study of the six cysteines of the E1 subunit of the pyruvate dehydrogenase multienzyme complex from Escherichia coli: none is essential for activity. Biochemistry (1998) 1.03
Comparison of surface proteins of Anaplasma marginale grown in tick cell culture, tick salivary glands, and cattle. Infect Immun (1999) 1.02
Analysis of middle tumor antigen and pp60c-src interactions in polyomavirus-transformed rat cells. J Virol (1987) 1.02
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer (2000) 0.98
The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer (2003) 0.98
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer (2007) 0.98
Production of muons from heavy flavor decays at forward rapidity in pp and Pb-Pb collisions at sqrt[s(NN)]=2.76 TeV. Phys Rev Lett (2012) 0.98
Functional characterization of MT3-MMP in transfected MDCK cells: progelatinase A activation and tubulogenesis in 3-D collagen lattice. FASEB J (2000) 0.97
PIASy stimulates HIF1α SUMOylation and negatively regulates HIF1α activity in response to hypoxia. Oncogene (2010) 0.97
Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients. Br J Cancer (1999) 0.96
Sjögren's syndrome and the epithelial target: a comprehensive review. J Autoimmun (2013) 0.96
Removal of groundwater arsenic using a household filter with iron spikes and stainless steel. J Environ Manage (2013) 0.96
Biotin and digoxigenin as labels for light and electron microscopy in situ hybridization probes: where do we stand? J Histochem Cytochem (1997) 0.96
Search for the rare leptonic decay B--->tau-nutau. Phys Rev Lett (2005) 0.96
Engineering of complex polyketide biosynthesis--insights from sequencing of the monensin biosynthetic gene cluster. J Ind Microbiol Biotechnol (2001) 0.95
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol (2006) 0.95
Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia (2007) 0.94
Centrality dependence of the charged-particle multiplicity density at midrapidity in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2011) 0.93
Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol (2000) 0.92
LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor. Gene Expr (1999) 0.92
Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon. Liver (1987) 0.92
Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. Transpl Int (2000) 0.91
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer (2011) 0.91
Establishment and characterization of an Oklahoma isolate of Anaplasma marginale in cultured Ixodes scapularis cells. Vet Parasitol (2000) 0.91
Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand (2008) 0.90
BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol (2000) 0.90
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol (2011) 0.90
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol (2014) 0.89
Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol (2001) 0.89
Novel octaketide macrolides related to 6-deoxyerythronolide B provide evidence for iterative operation of the erythromycin polyketide synthase. Chem Biol (2000) 0.89
Construction of new vectors for high-level expression in actinomycetes. Gene (1998) 0.88
[Interrater reliability of the Spanish version of Schedule for Affective Disorders and Schizophrenia for School-Age Children--Present and Lifetime version (K-SADS-PL)]. Actas Esp Psiquiatr (2006) 0.88
Polyketide synthesis in vitro on a modular polyketide synthase. Chem Biol (1995) 0.88
Somatic diversification and affinity maturation of IgM and IgG anti-DNA antibodies in murine lupus. Eur J Immunol (1993) 0.88
Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. Br J Cancer (2012) 0.87
Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast (2004) 0.87
Midrapidity antiproton-to-proton ratio in pp collisons at sqrt[s]=0.9 and 7 TeV measured by the ALICE experiment. Phys Rev Lett (2010) 0.87
Dosimetric variations of target volumes and organs at risk in nasopharyngeal carcinoma intensity-modulated radiotherapy. Br J Radiol (2011) 0.87
Changes in body composition in women treated with gonadotropin-releasing hormone agonists. Maturitas (1998) 0.86
Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma (2010) 0.86
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). Br J Cancer (1998) 0.86
Expression, purification and characterization of recombinant mouse MT5-MMP protein products. FEBS Lett (1999) 0.86
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol (2013) 0.85
2-Oxo-3-alkynoic acids, universal mechanism-based inactivators of thiamin diphosphate-dependent decarboxylases: synthesis and evidence for potent inactivation of the pyruvate dehydrogenase multienzyme complex. Biochemistry (1997) 0.85
Engineering of a minimal modular polyketide synthase, and targeted alteration of the stereospecificity of polyketide chain extension. Chem Biol (1998) 0.85
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol (2011) 0.85
Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Ann Surg Oncol (1998) 0.85
Activity of pp60c-src protein kinase in human breast cancer. Mt Sinai J Med (1989) 0.84